 While Tilray has maintained its leading market share in the recreational cannabis market in Canada and the medical cannabis market in Europe, its Q2 earnings, which included a loss per share of -0.11 and an adjusted loss per share of -0.06, have left investors questioning the companys future growth prospects. 